XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 54.88

Change

-1.16 (-2.07)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 114.13B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 106.46B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.53 (-0.94%)

USD 100.12B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.08 (-0.49%)

USD 63.18B
VUSA:F Vanguard Funds Public Limited ..

-0.42 (-0.38%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.40 (-0.37%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 51.11B
XJSE:F Xtrackers II - Japan Governmen..

-0.10 (-1.28%)

USD 43.12B
0ZC:F Zscaler Inc

-0.62 (-0.34%)

USD 37.92B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.12% 83% B 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.12% 83% B 66% D+
Trailing 12 Months  
Capital Gain 5.52% 43% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.52% 38% F 45% F
Trailing 5 Years  
Capital Gain 46.04% 74% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.04% 74% C 54% F
Average Annual (5 Year Horizon)  
Capital Gain 11.05% 72% C 67% D+
Dividend Return 11.05% 70% C- 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.68% 64% D 89% A-
Risk Adjusted Return 103.54% 93% A 95% A
Market Capitalization 0.85B 73% C 55% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike